CTOs on the Move


 
CanReg, Inc. is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.marenon.com
  • 2098 Mississauga Rd
    Mississauga, ON CAN L5H 2K6
  • Phone: 416.571.8504

Executives

Name Title Contact Details

Similar Companies

Rappahannock Area Community Services Board

At RACSB, we are committed to helping community members lead the best lives possible, whether they need a little lift or a lifetime of support.

BioTek reMEDys

BioTek reMEDys is a specialty pharmacy that provides medications and support services to patients, physicians, nurses, payers, and pharma. They focus on specific disease states and provide expert care to ensure appropriate dosages and treatments. They ...

AKH

AKH is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ASG Medical Systems

ASG Medical Systems is a West Palm Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.